Brief: Ovid Therapeutics Regains Compliance With Nasdaq Listing Rule - SEC Filing
16/09/2025 13:58
Sept 16 (Reuters) - Ovid Therapeutics Inc OVID.O: OVID THERAPEUTICS - REGAINS COMPLIANCE WITH NASDAQ LISTING RULE - SEC FILING Source text: [ID:n0001193125-25-204308] Further company coverage: OVID.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ovid Therapeutics
See all newsOvid Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Ovid Therapeutics Q2 revenue beats estimates
Brief: Ovid Therapeutics Q2 EPS USD -0.08
Ovid Therapeutics Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Ovid Therapeutics Appoints Leading Physician-Scientist And Biotech Innovator Anna Greka, M.D., Ph.D., To Board Of Directors